Metastatic breast cancer trials recruiting in Florida
All Metastatic breast cancer trials nationally
23
Recruiting in Florida
17
Cities with sites
Cities in Florida
Tampa 8Miami 6Jacksonville 4Plantation 4Orlando 3Sarasota 3Lake Mary 2Altamonte Springs 1Aventura 1Coral Gables 1Coral Springs 1Deerfield Beach 1
Recruiting trials in Florida
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- A Study of HLD-0117 in Patients With Metastatic Breast Cancer
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Comprehensive Outcomes for After Cancer Health
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- PRE-ISPY Phase I/II Oncology Platform Program
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study